Development of novel therapeutic strategies targeting cellular metabolism in autoimmune diseases
Description: The glutamine metabolism inhibitor 6-diazo-5-oxo-L-norleucin (DON) and the mTOR inhibitor rapamycin suppressed T cell proliferation. In addition, the combined use of both showed a significantly stronger growth inhibitory effect than the case of a single agent. DON and rapamycin suppressed Th17 cell differentiation. DON suppressed the differentiation of bone marrow cells into dendritic cells and macrophages and promoted the differentiation into bone marrow-derived inhibitory cells (MDSC).Furthermore, the effect of both drugs on suppressing mouse arthritis was examined. We demonstrated that combined treatment with rapamycin and DON additively ameliorated the arthritis in SKG mice, possibly by suppressing CD4+ T cell proliferation and Th17 differentiation.
Amount: ¥4,420,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2018-04-01
End date: 2021-03-31
Investigator: Jun Saegusa (lead)
Institution: Kobe University
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Funded outputs count: 7
Funder award ID: 18K08387
OpenAlex ID: G941956168
